These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38072889)

  • 1. Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration.
    Singh A; Panhelainen A; Reunanen S; Luk KC; Voutilainen MH
    Eur J Neurosci; 2024 Jan; 59(1):132-153. PubMed ID: 38072889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
    Singh A; Panhelainen A; Voutilainen MH
    Neurosci Lett; 2023 Nov; 816():137510. PubMed ID: 37802418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo.
    Albert K; Raymundo DP; Panhelainen A; Eesmaa A; Shvachiy L; Araújo GR; Chmielarz P; Yan X; Singh A; Cordeiro Y; Palhano FL; Foguel D; Luk KC; Domanskyi A; Voutilainen MH; Huttunen HJ; Outeiro TF; Saarma M; Almeida MS; Airavaara M
    Mol Ther; 2021 Sep; 29(9):2821-2840. PubMed ID: 33940158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread.
    Pang CCC; Sørensen MH; Lee K; Luk KC; Trojanowski JQ; Lee VMY; Noble W; Chang RCC
    Neuropathol Appl Neurobiol; 2022 Oct; 48(6):e12829. PubMed ID: 35727707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
    Cui H; Elford JD; Alitalo O; Perez-Pardo P; Tampio J; Huttunen KM; Kraneveld A; Forsberg MM; Myöhänen TT; Jalkanen AJ
    Neurobiol Aging; 2023 Sep; 129():62-71. PubMed ID: 37271045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System.
    Björklund A; Nilsson F; Mattsson B; Hoban DB; Parmar M
    J Parkinsons Dis; 2022; 12(8):2307-2320. PubMed ID: 36189605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Effect of β-Wrapin AS69 in a Mouse Model Based on Alpha-Synuclein Overexpression.
    Höfs L; Geißler-Lösch D; Wunderlich KM; Szegö EM; Van den Haute C; Baekelandt V; Hoyer W; Falkenburger BH
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons.
    Er S; Hlushchuk I; Airavaara M; Chmielarz P; Domanskyi A
    J Vis Exp; 2020 Aug; (162):. PubMed ID: 32865527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.
    Polinski NK; Volpicelli-Daley LA; Sortwell CE; Luk KC; Cremades N; Gottler LM; Froula J; Duffy MF; Lee VMY; Martinez TN; Dave KD
    J Parkinsons Dis; 2018; 8(2):303-322. PubMed ID: 29400668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.